Enzyme replacement is disease-specific supportive biology
Enzyme replacement therapy supplies a functional enzyme for selected lysosomal and other inherited disorders. It may improve specific organ outcomes but does not necessarily reach every tissue equally or reverse established damage.
Eligibility, dose and monitoring are tied to the exact product and diagnosis. Infusion reactions, antibodies, venous access and lifelong treatment burden belong in the initial decision.
Treatment benefit differs across organs and disease stage; stabilization can be a meaningful goal even when established injury is irreversible.
Who may be considered?
This review may help when the phenotype and existing evidence create a focused question about disease-specific enzyme replacement therapy.
- A confirmed disorder with an available approved enzyme product.
- A symptomatic or presymptomatic patient meeting product criteria.
- A person with infusion reaction or inadequate-response concerns.
- A patient comparing local and international access.
- A family needing home-infusion versus centre-infusion review.
What the specialist team must confirm
The team confirms enzyme, metabolite and genetic evidence, organ burden, product indication, weight-based dose, antibodies, allergy risk, cardiac and respiratory status, venous access and the ability to maintain uninterrupted therapy.
Key points for this treatment
From confirmed deficiency to sustainable infusion care
Product eligibility, realistic organ goals and reliable long-term delivery are assessed together.
Response, antibodies and continuity of access
Follow-up uses disease-specific biomarkers, organ tests and functional measures. A laboratory change alone may not equal meaningful clinical benefit.
Infusion reactions and antidrug antibodies are assessed in context. Any international plan should protect uninterrupted supply and emergency coverage.
Limits, burdens and realistic expectations
Treatment may not cross the blood-brain barrier or reverse established organ damage. Infusion reactions and antibodies can occur, lifelong access is expensive, and benefits vary by disease stage.
Severe infusion reaction, breathing difficulty, fainting, chest pain or rapid swelling requires emergency care and immediate cessation under the infusion team.